GSK256066 significantly reduced baseline Nox2 activity in eosinophils from healthy subjects. In mouse IDG-SW3 osteoblast-to-late-osteocyte cells treated in OIM, GSK256066 significantly reduced intracellular and extracellular sclerostin levels compared with OIM controls. In neutrophils from healthy individuals, GSK256066 reduced Nox2 activity in the absence or presence of influenza or fMLP, whereas RSV exposure made neutrophils unresponsive to both PDE4 inhibitors. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Baseline oxidase activity in healthy human eosinophils
Cell-based study · eosinophils from healthy subjects (white; n = 8) [1]
In eosinophils from healthy subjects, pretreatment with GSK256066 significantly reduced baseline Nox2 activity relative to the normalized baseline value.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.1 nmol/L
- Exposure duration
- 30 minutes
- Method
- pretreated with PDE4 inhibitors
- Vehicle
- 0.1% final DMSO concentration in the assays
Methods and source locations
Compound reported in the paper: GSK256066
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
MATERIALS AND METHODS > Compounds (S20, S21); MATERIALS AND METHODS > Assays > Amplex Red hydrogen peroxide assay (S22, S23); Figure 3 legend (S71, S75)
Nox2 activity: Nox2 activity; comparator: normalized baseline value — Figure 3 legend (S71)
Sclerostin levels in a mouse osteoblast-to-late-osteocyte cell line
Cell-based study · Mouse osteoblast-to-late-osteocyte cell line IDG-SW3 [2]
In a mouse osteoblast-to-late-osteocyte cell line cultured in OIM, GSK256066 significantly reduced intracellular and extracellular sclerostin levels compared with OIM controls.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.001‒1 μM
- Exposure duration
- 21 days
- Method
- in OIM
- Vehicle
- DMSO
- Co-treatment
- Other interventions in this design: ascorbic acid 50 μg/mL; β-glycerophosphate 4 mM. Compound effect isolated by the comparison: compared to the OIM controls.
Methods and source locations
Compound reported in the paper: GSK256066
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Results > 2.3. Intracellular and Extracellular Levels of Sclerostin in Mouse IDG-SW3 Cells (S39); 4. Materials and Methods > 4.1. Materials (S60); 4. Materials and Methods > 4.4. IDG-SW3 Cell Culture (S71, S73); Figure 5 legend (S106, S108); Figure 7 legend (S114)
intracellular sclerostin concentration: intracellular sclerostin concentration; comparator: OIM controls — 2. Results > 2.3. Intracellular and Extracellular Levels of Sclerostin in Mouse IDG-SW3 Cells (S39); Figure 5 legend (S106)
Oxidase activity in healthy human neutrophils
Cell-based study · Neutrophils from healthy individuals [1]
Neutrophils from healthy individuals showed a reduced Nox2 activity. Neutrophils were responsive to both PDE4 inhibitors, but RSV exposure eradicated inhibition by PDE4 inhibitors.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1.0 nmol/L
- Exposure duration
- 30 minutes
- Method
- pretreated with PDE4 inhibitors
- Vehicle
- 0.1% final DMSO concentration in the assays
Methods and source locations
Compound reported in the paper: GSK256066
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
MATERIALS AND METHODS > Compounds (S20, S21); MATERIALS AND METHODS > Assays > Amplex Red hydrogen peroxide assay (S22, S23); RESULTS > Effect of PDE4 inhibitors on Nox2 activity in virus‐exposed eosinophils and neutrophils (S59); Figure 3 legend (S74, S75)
Nox2 activity: Nox2 activity; comparator: normalized baseline value — RESULTS > Effect of PDE4 inhibitors on Nox2 activity in virus‐exposed eosinophils and neutrophils (S59)